Cargando…

A Comparison of Efficacy and Safety of Two Lipid-Based Lubricant Eye Drops for the Management of Evaporative Dry Eye Disease

PURPOSE: The aim of this study was to compare the efficacy of two lipid-based lubricant eye drops in patients with lipid-deficient dry eye. METHODS: This Phase IV, multicenter, prospective, double-masked study enrolled adults (aged ≥18 years) who had a tear film breakup time (TFBUT) of ≤15 seconds(s...

Descripción completa

Detalles Bibliográficos
Autores principales: Jerkins, Gary, Greiner, Jack V, Tong, Louis, Tan, Jacqueline, Tauber, Joseph, Mearza, Ali, Srinivasan, Sruthi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308126/
https://www.ncbi.nlm.nih.gov/pubmed/32606581
http://dx.doi.org/10.2147/OPTH.S256351
_version_ 1783548935767326720
author Jerkins, Gary
Greiner, Jack V
Tong, Louis
Tan, Jacqueline
Tauber, Joseph
Mearza, Ali
Srinivasan, Sruthi
author_facet Jerkins, Gary
Greiner, Jack V
Tong, Louis
Tan, Jacqueline
Tauber, Joseph
Mearza, Ali
Srinivasan, Sruthi
author_sort Jerkins, Gary
collection PubMed
description PURPOSE: The aim of this study was to compare the efficacy of two lipid-based lubricant eye drops in patients with lipid-deficient dry eye. METHODS: This Phase IV, multicenter, prospective, double-masked study enrolled adults (aged ≥18 years) who had a tear film breakup time (TFBUT) of ≤15 seconds(s), and unanesthetized Schirmer I test of ≥3 mm to ≤12 mm in at least one eye, at both screening and baseline visits. Eligible patients (n=231) were randomized (1:1) and received either Systane(®) Balance (SYSB; n=117) or Refresh(®) Optive Advanced (RFO-Ad, n=114), four-times a day, for 35 days. The primary endpoint was non-inferiority for change from baseline in TFBUT at Day 35 (non-inferiority was established if the lower limit of the 95% confidence interval (CI) for the difference between the treatment groups was > –1.0 s); secondary endpoints (test of superiority) were change in TFBUT and global ocular discomfort visual analog scale (VAS) score at Day 35. Other endpoints included the impact of dry eye on everyday life (IDEEL) treatment satisfaction scores (inconvenience and effectiveness) and safety. RESULTS: At Day 35, the mean change from baseline in TFBUT was 0.998 s in the SYSB and 0.868 s in the RFO-Ad groups with a treatment difference: 0.130 s; (95% CI −0.34, 0.60; P<0.0001) demonstrating non-inferiority of SYSB to RFO-Ad. The global ocular discomfort VAS scores improved in both groups, with a mean change from baseline of –9.7 and –8.8 in SYSB and RFO-Ad groups (treatment difference –0.8; P=0.62), respectively. No meaningful difference was observed in IDEEL treatment effectiveness and treatment inconvenience scores between SYSB vs RFO-Ad (P>0.05 for treatment difference). Both treatments were well tolerated. CONCLUSION: SYSB lubricant eye drops were non-inferior to RFO-Ad for improvement in TFBUT in patients with lipid-deficient dry eye. Both lubricant eye drops improved TFBUT and ocular discomfort scores in patients with lipid-deficient dry eye.
format Online
Article
Text
id pubmed-7308126
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-73081262020-06-29 A Comparison of Efficacy and Safety of Two Lipid-Based Lubricant Eye Drops for the Management of Evaporative Dry Eye Disease Jerkins, Gary Greiner, Jack V Tong, Louis Tan, Jacqueline Tauber, Joseph Mearza, Ali Srinivasan, Sruthi Clin Ophthalmol Original Research PURPOSE: The aim of this study was to compare the efficacy of two lipid-based lubricant eye drops in patients with lipid-deficient dry eye. METHODS: This Phase IV, multicenter, prospective, double-masked study enrolled adults (aged ≥18 years) who had a tear film breakup time (TFBUT) of ≤15 seconds(s), and unanesthetized Schirmer I test of ≥3 mm to ≤12 mm in at least one eye, at both screening and baseline visits. Eligible patients (n=231) were randomized (1:1) and received either Systane(®) Balance (SYSB; n=117) or Refresh(®) Optive Advanced (RFO-Ad, n=114), four-times a day, for 35 days. The primary endpoint was non-inferiority for change from baseline in TFBUT at Day 35 (non-inferiority was established if the lower limit of the 95% confidence interval (CI) for the difference between the treatment groups was > –1.0 s); secondary endpoints (test of superiority) were change in TFBUT and global ocular discomfort visual analog scale (VAS) score at Day 35. Other endpoints included the impact of dry eye on everyday life (IDEEL) treatment satisfaction scores (inconvenience and effectiveness) and safety. RESULTS: At Day 35, the mean change from baseline in TFBUT was 0.998 s in the SYSB and 0.868 s in the RFO-Ad groups with a treatment difference: 0.130 s; (95% CI −0.34, 0.60; P<0.0001) demonstrating non-inferiority of SYSB to RFO-Ad. The global ocular discomfort VAS scores improved in both groups, with a mean change from baseline of –9.7 and –8.8 in SYSB and RFO-Ad groups (treatment difference –0.8; P=0.62), respectively. No meaningful difference was observed in IDEEL treatment effectiveness and treatment inconvenience scores between SYSB vs RFO-Ad (P>0.05 for treatment difference). Both treatments were well tolerated. CONCLUSION: SYSB lubricant eye drops were non-inferior to RFO-Ad for improvement in TFBUT in patients with lipid-deficient dry eye. Both lubricant eye drops improved TFBUT and ocular discomfort scores in patients with lipid-deficient dry eye. Dove 2020-06-18 /pmc/articles/PMC7308126/ /pubmed/32606581 http://dx.doi.org/10.2147/OPTH.S256351 Text en © 2020 Jerkins et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Jerkins, Gary
Greiner, Jack V
Tong, Louis
Tan, Jacqueline
Tauber, Joseph
Mearza, Ali
Srinivasan, Sruthi
A Comparison of Efficacy and Safety of Two Lipid-Based Lubricant Eye Drops for the Management of Evaporative Dry Eye Disease
title A Comparison of Efficacy and Safety of Two Lipid-Based Lubricant Eye Drops for the Management of Evaporative Dry Eye Disease
title_full A Comparison of Efficacy and Safety of Two Lipid-Based Lubricant Eye Drops for the Management of Evaporative Dry Eye Disease
title_fullStr A Comparison of Efficacy and Safety of Two Lipid-Based Lubricant Eye Drops for the Management of Evaporative Dry Eye Disease
title_full_unstemmed A Comparison of Efficacy and Safety of Two Lipid-Based Lubricant Eye Drops for the Management of Evaporative Dry Eye Disease
title_short A Comparison of Efficacy and Safety of Two Lipid-Based Lubricant Eye Drops for the Management of Evaporative Dry Eye Disease
title_sort comparison of efficacy and safety of two lipid-based lubricant eye drops for the management of evaporative dry eye disease
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308126/
https://www.ncbi.nlm.nih.gov/pubmed/32606581
http://dx.doi.org/10.2147/OPTH.S256351
work_keys_str_mv AT jerkinsgary acomparisonofefficacyandsafetyoftwolipidbasedlubricanteyedropsforthemanagementofevaporativedryeyedisease
AT greinerjackv acomparisonofefficacyandsafetyoftwolipidbasedlubricanteyedropsforthemanagementofevaporativedryeyedisease
AT tonglouis acomparisonofefficacyandsafetyoftwolipidbasedlubricanteyedropsforthemanagementofevaporativedryeyedisease
AT tanjacqueline acomparisonofefficacyandsafetyoftwolipidbasedlubricanteyedropsforthemanagementofevaporativedryeyedisease
AT tauberjoseph acomparisonofefficacyandsafetyoftwolipidbasedlubricanteyedropsforthemanagementofevaporativedryeyedisease
AT mearzaali acomparisonofefficacyandsafetyoftwolipidbasedlubricanteyedropsforthemanagementofevaporativedryeyedisease
AT srinivasansruthi acomparisonofefficacyandsafetyoftwolipidbasedlubricanteyedropsforthemanagementofevaporativedryeyedisease
AT jerkinsgary comparisonofefficacyandsafetyoftwolipidbasedlubricanteyedropsforthemanagementofevaporativedryeyedisease
AT greinerjackv comparisonofefficacyandsafetyoftwolipidbasedlubricanteyedropsforthemanagementofevaporativedryeyedisease
AT tonglouis comparisonofefficacyandsafetyoftwolipidbasedlubricanteyedropsforthemanagementofevaporativedryeyedisease
AT tanjacqueline comparisonofefficacyandsafetyoftwolipidbasedlubricanteyedropsforthemanagementofevaporativedryeyedisease
AT tauberjoseph comparisonofefficacyandsafetyoftwolipidbasedlubricanteyedropsforthemanagementofevaporativedryeyedisease
AT mearzaali comparisonofefficacyandsafetyoftwolipidbasedlubricanteyedropsforthemanagementofevaporativedryeyedisease
AT srinivasansruthi comparisonofefficacyandsafetyoftwolipidbasedlubricanteyedropsforthemanagementofevaporativedryeyedisease